“Over the past year, we have strengthened the integrated data package for atacicept as a potentially disease-modifying treatment for patients with IgA Nephropathy (IgAN) and rapidly advanced the pivotal Phase 3 ORIGIN 3 clinical trial, which is expected to support our BLA submission to the FDA next year,” said Marshall Fordyce, M.D., Founder and CEO of Vera Therapeutics. “We believe atacicept 72-week data from the Phase 2b ORIGIN trial are consistent with a profile of true disease modification. Our clinical successes to date, including the announcement of multiple positive data readouts from the Phase 2b ORIGIN trial of atacicept in patients with IgAN, as well as executing on the ORIGIN 3 study, have gained broad attention across the clinical landscape, and we have attracted several respected industry veterans to expand our team in support of our advancing pipeline.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on VERA:
- VERA Upcoming Earnings Report: What to Expect?
- Vera Therapeutics to Participate at the 44th Annual TD Cowen Health Care Conference
- Fly Insider: Skye Bioscience, Coinbase among week’s notable insider trades
- Vera Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
- Vera Therapeutics director buys $5.0M in common stock